2cureX Investor Relations Material
Latest events
Investor Update
2cureX
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from 2cureX
Access all reports
2cureX AB is a medtech company focused on improving cancer treatment through functional drug sensitivity testing. Its flagship product, IndiTreat, is an in vitro diagnostic (IVD) test that helps predict a cancer patient’s response to different drugs, enabling personalized treatment plans. IndiTreat is designed to assist in treating colorectal, ovarian, and pancreatic cancers, among others. The company is headuqartered in Copenhagen, Denmark, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
2CUREX
Country
🇸🇪 Sweden